A0A2J8QUE2 (A0A2J8QUE2_PANTR) Pan troglodytes (Chimpanzee)
T0049552 isoform 1 UniProtKBInterProInteractive Modelling
176 aa; Sequence (Fasta) ;
1 identical sequence: Homo sapiens: P01850
It is possible new templates exist for this target since these models were created.
Available Structures
83 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| TCR GDN detergent micelle |
Heteromer P01848; P01850; P04234; P07766; P09693; P20963; | 97.67 | 2×NAG; 3×NAG; 5×NAG; 2×CLR; | |||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; | 95.35 | ||||
| Crystal structure of ELS4 TCR at 1.4A |
Heteromer P01850; Q6P4G7; | 98.45 | ||||
| A structural basis for immunodominant human T-cell receptor recognition. |
Heteromer P01848; P01850; P04439; P61769; | 96.9 | ||||
| Immune Receptor |
Heteromer P01848; P01850; | 97.67 | ||||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; P04439; P61769; P78358; | 95.35 | ||||
| Structural and kinetic basis for heightened immunogenicity of T cell vaccines |
Heteromer A0A0B4J279; A0A0K0K1A5; P01848; P01850; P04439; P61769; P78358; | 95.35 | ||||
| Structural basis for recognition of mutant self by a tumor-specific, MHC class II-restricted TCR |
Heteromer P01848; P01850; | 98.45 | ||||
| T cell receptor CO3 |
Heteromer A0A0C4DH28; A0A1B0GX56; P01848; P01850; | 96.12 | 1×EDO; 2×SO4; | |||
| Crystal structure of JKA6 TCR |
Heteromer A0A075B6T6; A0A5B6; P01848; P01850; | 94.57 | ||||
| Crystal Structure of clone42 TCR |
Heteromer P01848; P01850; | 96.12 | ||||
| Crystal Structure of clone18 TCR |
Heteromer P01848; P01850; | 96.12 | ||||
| Structure and binding kinetics of three different human CD1d-alpha- Galactosylceramide-specific T c… |
Heteromer P01848; P01850; | 96.9 | ||||
| Crystal structure of the ternary complex between human T cell receptor, staphylococcal enterotoxin … |
Heteromer P01848; P01850; P01903; P01911; P0A0M0; Q03909; | 96.12 | 4×GOL; 1×NA; | |||
| Crystal Structure of CA5 TCR-HLA B*3505-LPEP complex |
Heteromer C5MK56; P01848; P01850; P61769; Q3KSS8; | 96.12 | 3×NA; 8×IOD; | |||
| Crystal structure of TK3 TCR-HLA-B*35:08-HPVG complex |
Heteromer C5MK56; P01848; P01850; P03211; P61769; | 96.12 | 2×CL; 3×NA; | |||
| High Affinity alpha24-beta17 T Cell Receptor for A2 HLA-Melanoma peptide complex |
Heteromer P01848; P01850; | 95.35 | 5×EDO; 1×GOL; 3×SO4; | |||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P04439; P61769; Q16655; | 95.35 | 2×EPE; 7×SO4; | |||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P04439; P61769; | 95.35 | 1×TAM; 11×SO4; | |||
| The crystal structure of LC13 TcR in complex with HLAB8-EBV peptide complex |
Heteromer P01848; P01850; P01889; P61769; Q3KST2; | 96.9 | ||||
| Crystal structure of TK3 TCR-HLA-B*35:01-HPVG-Q5 complex |
Heteromer C5MK56; P01848; P01850; P03211; P61769; | 96.12 | 3×SO4; | |||
| Crystal Structure of SB27 TCR in complex with HLA-B*3508-13mer peptide |
Heteromer P01848; P01850; P01889; P03206; P61769; | 96.12 | 7×IOD; | |||
| Crystal structure of TK3 TCR-HLA-B*35:08-HPVG-D5 complex |
Heteromer C5MK56; P01848; P01850; P61769; Q3KSS4; | 96.12 | ||||
| Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr… |
Heteromer P01848; P01850; P61769; Q3KSU1; Q8WLS4; | 96.9 | 11×GOL; 7×SO4; 1×MES; | |||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5K-4-[3-Indo… |
Heteromer P01848; P01850; P04439; P61769; | 96.9 | 5×SO4; 13×GOL; 1×3IB; | |||
| Structure and binding kinetics of three different human CD1d-alpha- Galactosylceramide-specific T c… |
Heteromer P01848; P01850; | 96.9 | ||||
| Structure of the HLA-E-VMAPRTLIL/KK50.4 TCR complex |
Heteromer P01848; P01850; P13747; P16780; P61769; | 96.12 | 5×IOD; | |||
| Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLKAWTF a mimotope |
Heteromer P01848; P01850; P01889; P61769; | 96.9 | ||||
| Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances af… |
Heteromer P01848; P01850; P04439; P61769; P78358; | 95.35 | ||||
| Crystal structure of ELS4 TCR bound to HLA-B*3501 presenting EBV peptide EPLPQGQLTAY at 1.7A |
Heteromer P01848; P01850; P01889; P03206; P61769; | 98.45 | ||||
| CD1a-sulfatide-gdTCR complex |
Heteromer A0A0C4DH28; A0A1B0GX56; P01848; P01850; P06126; P61769; | 96.12 | 1×CIS; 6×EDO; 1×NAG; 1×PEG; 2×SO4; | |||
| Ternary crystal structure of the NKT TCR-CD1d-alpha-galactosylceramide analogue-OCH |
Heteromer P01848; P01850; P01887; P11609; | 96.12 | 3×NAG; 2×PEG; 1×NAG; 1×FEE; 1×D12; | |||
| Crystal Structure of the LC13 TCR in complex with HLA B*4405 bound to EEYLQAFTY a self peptide from… |
Heteromer P01848; P01850; P01889; P61769; | 96.9 | ||||
| Preservation of peptide specificity during TCR-MHC contact dominated affinity enhancement of a mela… |
Heteromer P01848; P01850; P04439; P61769; | 95.35 | 4×SO4; 2×GOL; | |||
| TCR-peptide specificity overrides affinity enhancing TCR-MHC interactions |
Heteromer H2RG00; K7N5N2; O14746; P01850; P04439; P61769; | 96.9 | 1×GOL; 2×EDO; | |||
| Crystal Structure of SB47 TCR-HLA B*3505-LPEP complex |
Heteromer C5MK56; P01848; P01850; P61769; Q3KSS8; | 96.12 | 1×NA; 2×MG; | |||
| Crystal structure of the 5F TCR in complex with HLA-DP4-Ply |
Heteromer P01848; P01850; P04440; P20036; Q04IN8; | 99.22 | 1×NAG; 2×NAG; 3×EDO; | |||
| Structural basis for recognition of mutant self by a tumor-specific, MHC class II-restricted TCR |
Heteromer P01848; P01850; P01903; P01911; P60174; | 98.45 | ||||
| Ternary crystal structure of the mouse NKT TCR-CD1d-4'deoxy-alpha-galactosylceramide |
Heteromer P01848; P01850; P01887; P11609; | 96.12 | 2×NAG; 1×NAG; 1×4GH; 1×PEG; | |||
| Structural basis for recognition of mutant self by a tumor-specific, MHC class II-restricted TCR |
Heteromer P01848; P01850; P01903; P01911; P60174; | 98.45 | ||||
| Crystal Structure of CF34 TCR in complex with HLA-B8/FLR |
Heteromer P01850; P01889; P61769; | 96.12 | 5×CD; 6×CL; 6×NA; | |||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(3,4-difluo… |
Heteromer P01850; P04439; P61769; | 96.9 | 6×GOL; | |||
| The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5(4-fluoroPh… |
Heteromer P01848; P01850; P04439; P61769; | 96.9 | 4×GOL; | |||
| Ternary crystal structure of the mouse NKT TCR-CD1d-C20:2 |
Heteromer P01848; P01850; P01887; P11609; | 96.12 | 3×NAG; 1×DB3; | |||
| Crystal structure of mouse CD1d-alpha-galactosylceramide with mouse Valpha14-Vbeta8.2 NKT TCR |
Heteromer P01850; P01887; P11609; | 96.12 | 1×NAG; 2×NAG; 1×AGH; | |||
| CD1a-dideoxymycobactin-gdTCR complex |
Heteromer A0A0C4DH28; A0A1B0GX56; P01848; P01850; P06126; P61769; | 96.12 | 2×EDO; 1×WGR; 1×SO4; | |||
| Germline-governed recognition of a cancer epitope by an immunodominant human T cell receptor |
Heteromer P01848; P01850; P61769; Q16655; Q8WLS4; | 95.35 | 2×GOL; 2×SO4; | |||
| Complex of Streptococcal pyrogenic enterotoxin C (SpeC) with a human T cell receptor beta chain (Vb… |
Heteromer P01850; Q8NKX2; | 100 | ||||
| Ternary crystal structure of the mouse NKT TCR-CD1d-3'deoxy-alpha-galactosylceramide |
Heteromer P01848; P01850; P01887; P11609; | 96.12 | 3×NAG; 1×3GH; | |||
| Crystal structure of the B5 TCR in complex with HLA-DP4-Ply |
Heteromer P01848; P01850; P04440; P20036; Q04IN8; | 98.45 | 1×NAG; 1×EDO; 1×NAG; | |||
| Structure of mouse Va14Vb8.2NKT TCR-mouse CD1d-a-C-Galactosylceramide complex |
Heteromer P01848; P01850; P01887; P11609; | 96.12 | 1×NAG; 1×QUX; 2×NAG; | |||
| CD1a-endo-gdTCR complex |
Heteromer A0A0C4DH28; A0A1B0GX56; P01848; P01850; P06126; P61769; | 96.03 | 1×PEG; 1×SO4; | |||
| Crystal structure of the B1 TCR in complex with HLA-DP4-Ply |
Heteromer P01848; P01850; P04440; P20036; Q04IN8; | 98.45 | 1×NAG; 2×NAG; | |||
| Structure and binding kinetics of three different human CD1d-alpha- Galactosylceramide specific T c… |
Heteromer P01850; | 96.12 | ||||
| G12V-TCR complex with HLA-A3 |
Heteromer P01116; P01848; P01850; P04439; P61769; | 96.12 | ||||
| Structure of human MAIT TCR in complex with human MR1-6-FP |
Heteromer P01850; P61769; Q95460; | 96.09 | 1×6FP; | |||
| Crystal structure of the complex between human T cell receptor and staphylococcal enterotoxin |
Heteromer P01848; P01850; P0A0M0; | 96.09 | 3×GOL; 1×NA; | |||
| BK6 TCR apo structure |
Heteromer P01848; P01850; | 97.66 | ||||
| Crystal structure of TCR-MR1 ternary complex and non-covalently bound 5-(2-oxopropylideneamino)-6-D… |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 96.09 | 2×Q87; 1×GOL; | |||
| Crystal Structure of a Complex of a Human alpha/beta-T cell Receptor, Influenza HA Antigen Peptide,… |
Heteromer P01848; P01850; P01903; P01911; P03437; | 99.22 | 1×NAG; 2×NAG; | |||
| CRYSTAL STRUCTURE OF A COMPLEX OF A HUMAN ALPHA/BETA-T CELL RECEPTOR, INFLUENZA HA ANTIGEN PEPTIDE,… |
Heteromer P01848; P01850; P01903; P01911; P03437; | 99.22 | 2×NAG; | |||
| JR5.1 protein complex |
Heteromer P01850; P01909; P04722; Q2YD82; Q5Y7D3; | 96.09 | 2×NAG; | |||
| CD1a ternary complex with lysophosphatidylcholine and BK6 TCR |
Heteromer P01848; P01850; P06126; P61769; | 97.66 | 2×NAG; 1×42H; | |||
| S16 protein complex |
Heteromer P01850; P01909; P04722; Q2YD82; Q5Y7D3; | 96.09 | 2×NAG; 1×CA; | |||
| Crystal structure of a human MAIT TCR in complex with bovine MR1 |
Heteromer C1ITJ8; P01850; P01888; Q6P4G7; | 96.09 | 3×SO4; | |||
| CD1a ternary complex with endogenous lipids and BK6 TCR |
Heteromer P01848; P01850; P06126; P61769; | 97.66 | 1×NAG; 1×OLA; | |||
| Ternary crystal structure of the mouse NKT TCR-CD1d-alpha-glucosylceramide(C20:2) |
Heteromer P01848; P01850; P01887; P11609; | 96.09 | 2×NAG; 1×NAG; 1×DB6; | |||
| D2 protein complex |
Heteromer P01850; P01909; P04722; Q2YD82; Q5Y7D3; | 96.09 | 1×NAG; | |||
| Protein complex |
Heteromer K7N5N2; P01850; P01909; P01920; P18573; | 96.09 | 2×NAG; | |||
| S2 protein complex |
Heteromer P01850; P01909; P04722; Q2YD82; Q5Y7D3; | 96.09 | 1×NAG; 1×CA; | |||
| Immune Receptor |
Heteromer K7N5N2; P01850; | 96.09 | 1×GLC; | |||
| Crystal structure of a human MAIT TCR in complex with a bacterial antigen bound to humanized bovine… |
Heteromer C1ITJ8; P01850; P01888; Q6P4G7; | 95.94 | 1×1XL; 4×SO4; | |||
| Crystal Structure of SEK-hVb5.1 |
Heteromer O54476; P01850; | 96.85 | ||||
| Crystal structure of TCR-MR1 ternary complex and covalently bound 5-(2-oxopropylideneamino)-6-D-rib… |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 96.03 | 2×2LJ; 1×NA; | |||
| J809.B5 Y31A TCR bound to IAb3K |
Heteromer P01850; P14434; P14483; | 96.06 | ||||
| T cell response to a HIV reverse transcriptase epitope presented by the protective allele HLA-B*51:… |
Heteromer K7N5M3; P01850; P01889; P61769; R4WL38; | 95.28 | ||||
| Crystal structure of a human Valpha7.2/Vbeta13.2 MAIT TCR in complex with bovine MR1 |
Heteromer C1ITJ8; P01850; P01888; Q6P4G7; | 96.06 | 2×SO4; | |||
| TCR/HLA-DR2b/MBP-peptide complex |
Heteromer P01850; P01903; P01911; P02686; | 96.85 | 1×NAG; | |||
| Structure of human MAIT TCR in complex with human MR1-RL-6-Me-7-OH |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 96.03 | 1×1VY; 2×GOL; | |||
| The structure of human MAIT TCR in complex with MR1-K43A-RL-6-Me-7OH |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 96.03 | 1×GOL; 1×1VY; | |||
| Crystal structure of 3A6 TCR bound to MBP/HLA-DR2a |
Heteromer P01848; P01850; P01903; P02686; Q30154; | 96.8 | ||||
| Crystal structure of TCR-MR1 ternary complex bound to 5-(2-oxoethylideneamino)-6-D-ribitylaminourac… |
Heteromer P01850; P61769; Q6P4G7; Q95460; | 95.73 | 1×2L4; | |||
| Crystal structures of T cell receptor beta chains related to rheumatoid arthritis | homo-2-mer | 96.9 | ||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8es7.1.H | monomer | 0.74 | 100.00 | |||
| 8tw4.1.B | monomer | 0.59 | 97.71 | |||